Bellevue Group Ag Fate Therapeutics Inc Transaction History

Bellevue Group Ag

$5.02 Billion
Q4 2024

A detailed history of Bellevue Group Ag transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Bellevue Group Ag holds 4,839,779 shares of FATE stock, worth $6.87 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

4,839,779

Previous 4,839,779 -0.0%

Holding current value

$6.87 Million

Previous $16.9 Million 52.86%

% of portfolio

0.16%

Previous 0.29%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$3.54 - $8.35 $41,772 - $98,530	-11,800 Reduced 0.24%	4,839,779 $35.5 Million
Q3 2023 Nov 14, 2023	SELL	$2.02 - $5.04 $8,484 - $21,168	-4,200 Reduced 0.09%	4,851,579 $10.3 Million
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $23,320 - $61,159	-5,500 Reduced 0.11%	4,855,779 $27.7 Million
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $11 Million - $26.6 Million	1,115,193 Added 29.77%	4,861,279 $49.1 Million
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $4.12 Million - $7.07 Million	196,000 Added 5.52%	3,746,086 $84 Million
Q2 2022 Aug 11, 2022	SELL	$17.78 - $42.39 $469,392 - $1.12 Million	-26,400 Reduced 0.74%	3,550,086 $88 Million
Q1 2022 May 13, 2022	SELL	$29.67 - $60.28 $5.91 Million - $12 Million	-199,250 Reduced 5.28%	3,576,486 $139 Million
Q4 2021 Feb 10, 2022	BUY	$47.84 - $64.34 $25.7 Million - $34.6 Million	537,700 Added 16.61%	3,775,736 $221 Million
Q3 2021 Nov 12, 2021	BUY	$59.27 - $95.73 $37 Million - $59.8 Million	624,500 Added 23.89%	3,238,036 $192 Million
Q2 2021 Aug 12, 2021	BUY	$67.25 - $92.52 $27.2 Million - $37.4 Million	404,200 Added 18.3%	2,613,536 $227 Million
Q1 2021 May 12, 2021	BUY	$72.16 - $117.4 $7.35 Million - $12 Million	101,836 Added 4.83%	2,209,336 $182 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $4.19 Million - $11.1 Million	-110,000 Reduced 4.96%	2,107,500 $192 Million
Q3 2020 Nov 16, 2020	BUY	$30.41 - $40.5 $7.79 Million - $10.4 Million	256,100 Added 13.06%	2,217,500 $88.6 Million
Q2 2020 Aug 13, 2020	BUY	$20.21 - $35.23 $8.05 Million - $14 Million	398,200 Added 25.47%	1,961,400 $67.3 Million
Q1 2020 May 14, 2020	BUY	$17.28 - $31.88 $25.6 Million - $47.2 Million	1,480,400 Added 1787.92%	1,563,200 $34.7 Million
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $303,953 - $470,571	22,700 Added 37.77%	82,800 $1.62 Million
Q3 2019 Nov 14, 2019	BUY	$15.47 - $22.5 $17,017 - $24,750	1,100 Added 1.86%	60,100 $933,000
Q2 2019 Aug 14, 2019	BUY	$15.61 - $20.44 $920,990 - $1.21 Million	59,000 New	59,000 $1.2 Million

Others Institutions Holding FATE

# of Institutions

167

Shares Held

101M

Call Options Held

41.3K

Put Options Held

15.9K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $138M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Fate Therapeutics Inc Transaction History